RXK3.F SELLAS Life Sciences Group Inc
- Market cap
- EUR 1.75B
- P/E
- -
- P/B
- 12.48x
- ROE
- -26.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RXK3.F undervalued?
Graham numberThe Graham number of SELLAS Life Sciences Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SELLAS Life Sciences Group Inc fundamental analysis
No fundamental analysis for SELLAS Life Sciences Group Inc yet.
SELLAS Life Sciences Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to eval…
Full company profileSELLAS Life Sciences Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SELLAS Life Sciences Group Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.90M | 7.60M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | 1.90M | 7.40M | 900K | 0.00 | - | - | - |
| Operating Income | -31.9M | -21.2M | -31.1M | -17.2M | -17.0M | -25.3M | -42.0M | -37.9M | -31.5M | -28.3M | -39.8M |
| EBITDA | - | - | - | - | -16.7M | - | -32.0M | -37.9M | -31.5M | -28.3M | -39.8M |
| Net Income | -23.5M | -23.8M | -27.7M | -19.3M | -16.8M | -20.7M | -41.3M | -37.3M | -30.9M | -26.9M | -36.0M |
| EPS | - | -206 | -63 | -3.80 | -1.18 | -1.30 | -1.97 | -1.16 | -0.42 | -0.18 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 65.8M | 33.5M | 16.9M | 16.6M | 46.0M | 26.3M | 20.9M | 6.22M | 19.4M | 78.3M | 145M |
| Total Liabilities | 37.2M | 31.5M | 11.7M | 10.5M | 18.1M | 5.93M | 16.1M | 14.2M | 9.97M | 7.47M | 7.73M |
| Shareholders' Equity | 28.7M | 2.07M | 5.25M | 6.09M | 28.0M | 20.3M | 4.85M | -7.98M | 9.47M | 70.9M | 138M |
| Cash & Short-term Investments | 18.1M | 2.32M | 5.34M | 7.28M | 35.3M | 21.4M | 17.1M | 2.53M | 13.9M | 71.8M | 138M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.9M | -11.0M | -30.4M | -17.6M | -10.4M | -26.0M | -23.8M | -31.4M | -35.4M | -28.4M | -32.9M |
| Capital Expenditure | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.50M | 5.50M | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -11.0M | -30.4M | -17.6M | -10.4M | -26.0M | -28.3M | -36.9M | -35.4M | -28.4M | -32.9M |
| Ratios | |||||||||||
| ROE | -82.2% | -1,147.5% | -527.6% | -316.6% | -59.9% | -101.7% | -851.4% | - | -326.3% | -37.9% | -26.2% |
| ROA | -35.8% | -70.9% | -163.6% | -116.2% | -36.4% | -78.8% | -197.2% | -600.4% | -158.9% | -34.3% | -24.8% |
| Net Profit Margin | - | - | - | - | -881.9% | -272.4% | -4,130.1% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SELLAS Life Sciences Group Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 487K | 1.11 | - |
| 2017 | USD 487K | 4.22 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Nov 8, 2019.
Who owns SELLAS Life Sciences Group Inc
- Insiders 0.92%
- Institutions 36.89%
- Public & others 62.19%
- Shares outstanding 202M
- Free float 201M
SELLAS Life Sciences Group Inc company profile
- Company name
- SELLAS Life Sciences Group Inc
- Ticker
- RXK3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 7 Times Square, New York, NY, United States, 10036
- Phone
- 646 200 5278
- Website
- sellaslifesciences.com
About SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SELLAS Life Sciences Group Inc management
5- Dr. Angelos M. Stergiou M.D., ScD h.c.Founder, President, CEO & Director · born 1976
- Mr. John Thomas Burns CPASenior VP & CFO · born 1985
- Dr. Dragan Cicic M.D., MBASenior VP & Chief Development Officer · born 1963
- Ms. Stacy E. YeungVP, General Counsel & Corporate Secretary
- Mr. Andrew ElnatanSenior VP of Regulatory Affairs, CMC & Quality